Shuttle Pharmaceuticals Holdings, Inc.
SHPH
Rank in Stocks
#25631
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary... Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Share Price
$5.19
Last synced: 2026-11-09
Market Cap
$24.73M
Change (1 day)
-7.07%
Change (1 year)
-79.49%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Category
Healthcare
EPS for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
EPS as of June 2026 TTM: $-30.80
According to Shuttle Pharmaceuticals Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-30.80. At the end of 2025 the company had an EPS of $-71.60, an increase over its 2024 EPS of $-8.86K.
EPS history for Shuttle Pharmaceuticals Holdings, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-30.80 | -56.98% |
| 2025 | $-71.60 | -99.19% |
| 2024 | $-8.86K | 215,931.71% |
| 2023 | $-4.10 | 36.67% |
| 2022 | $-3.00 | 217.46% |
| 2021 | $-0.95 | 38.16% |
| 2020 | $-0.68 | 48.37% |
| 2018 | $-0.46 | 193.63% |
| 2017 | $-0.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -121.11% |
DE
|
|
| $6.08 | -119.73% |
DE
|
|
| $1.55 | -105.03% |
JP
|
|
| $3.66 | -111.88% |
CH
|
|
| $0.45 | -101.46% |
IL
|
Questions about Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS)
What is Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS)?
Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-30.80, as of Jun 2026.
What was Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) was $-71.60, compared with $-8.86K in 2024.
How has Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.68) and lowest in 2024 ($-8.86K).
How does Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Shuttle Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) ($-30.80) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.